Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabirnetug in Early Alzheimer's Disease
NCT04931459Phase 1Completed
- Sponsor
- Acumen Pharmaceuticals, Inc.
- Start
- Jun 2021
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing Sabirnetug (ACU193) with Placebo (2 arms). Primary endpoints: Incidence and Nature of Treatment-Related Adverse Events or Serious Adverse Events up to 28 weeks, Change in Clinical Laboratory Tests up to 28 weeks and 3 more. Started Jun 2021; status: completed.
02
Drugs
sabirnetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04931459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04931459.